{"id":"doi:10.1038/s41467-020-17670-y","kind":"article","title":"A decade of immune-checkpoint inhibitors in cancer therapy","authors":["Caroline Robert"],"author_count":1,"year":2020,"published":"2020-07-30","venue":"Nature Communications","cited_by":1607,"doi":"10.1038/s41467-020-17670-y","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41467-020-17670-y","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41467-020-17670-y","updated":null,"pmid":"32732879","pmcid":null,"openalex_id":"W3045946240","pdf_url":"https://www.nature.com/articles/s41467-020-17670-y.pdf","abstract":"Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.","abstract_license":"CC-BY (publisher license, via OpenAlex)","license":"cc-by","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Cancer Immunotherapy and Biomarkers"],"details":null,"provenance":"openalex","attribution":"Abstract of \"A decade of immune-checkpoint inhibitors in cancer therapy\" by Caroline Robert, https://doi.org/10.1038/s41467-020-17670-y, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}